One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease

被引:31
作者
Barreto, AC [1 ]
Franchi, SM [1 ]
Castro, CRP [1 ]
Lopes, AA [1 ]
机构
[1] USP, FM, InCor, Dept Cardiol Pediat & Cardiopatias Congenitas, BR-05403000 Sao Paulo, Brazil
关键词
sildenafil; pulmonary hypertension; pulmonary veno-occlusive disease; phosphodiesterase inhibitors;
D O I
10.1590/S0100-879X2005000200006
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
We hypothesized that chronic oral administration of the phosphodiesterase-5 inhibitor sildenafil could improve the exercise capacity and pulmonary hemodynamics in patients with pulmonary arterial hypertension (PAH) on the basis of previous short-term studies. We tested this hypothesis in 14 subjects with PAH, including seven patients with the idiopathic form and seven patients with atrial septal defects, but no other congenital heart abnormalities. Patients were subjected to a 6-min walk test and dyspnea was graded according to the Borg scale. Pulmonary flow and pressures were measured by Doppler echocardiography. Patients were given sildenafil, 75 mg orally three times a day, and followed up for 1 year. Sildenafil therapy resulted in the following changes: increase in the 6-min walk distance from a median value of 387 m (range 0 to 484 m) to 462 m (range 408 to 588 m; P < 0.01), improvement of the Borg dyspnea score from 4.0 (median value) to 3.0 (P < 0.01), and increased pulmonary flow (velocity-time integral) from a median value of 0.12 (range 0.08 to 0.25)to 0.23 (range 0.11 to 0.40; P < 0.01) with no changes in pulmonary pressures. In one patient with pulmonary veno-occlusive disease diagnosed by a lung biopsy, sildenafil had a better effect on the pulmonary wedge pressure than inhaled nitric oxide (15 and 29 mmHg, respectively, acute test). He walked 112 m at baseline and 408 m at one year. One patient died at 11 months of treatment. No other relevant events occurred. Thus, chronic administration of sildenafil improves the physical capacity of PAH patients and may be beneficial in selected cases of veno-occlusive disease.
引用
收藏
页码:185 / 195
页数:11
相关论文
共 40 条
[11]   Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension [J].
Ghofrani, HA ;
Schermuly, RT ;
Rose, F ;
Wiedemann, R ;
Kohstall, MG ;
Kreckel, A ;
Olschewski, H ;
Weissmann, N ;
Enke, B ;
Ghofrani, S ;
Seeger, W ;
Grimminger, F .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (08) :1139-1141
[12]   Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension [J].
Ghofrani, HA ;
Wiedemann, R ;
Rose, F ;
Olschewski, H ;
Schermuly, RT ;
Weissmann, N ;
Seeger, W ;
Grimminger, F .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (07) :515-522
[13]   Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial [J].
Ghofrani, HA ;
Wiedemann, R ;
Rose, F ;
Schermuly, RT ;
Olschewski, H ;
Weissmann, N ;
Gunther, A ;
Walmrath, D ;
Seeger, W ;
Grimminger, F .
LANCET, 2002, 360 (9337) :895-900
[14]   Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension [J].
Ghofrani, HA ;
Rose, F ;
Schermuly, RT ;
Olschewski, H ;
Wiedemann, R ;
Kreckel, A ;
Weissmann, N ;
Ghofrani, S ;
Enke, B ;
Seeger, W ;
Grimminger, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (01) :158-164
[15]   EXPRESSION OF ENDOTHELIN-1 IN THE LUNGS OF PATIENTS WITH PULMONARY-HYPERTENSION [J].
GIAID, A ;
YANAGISAWA, M ;
LANGLEBEN, D ;
MICHEL, RP ;
LEVY, R ;
SHENNIB, H ;
KIMURA, S ;
MASAKI, T ;
DUGUID, WP ;
STEWART, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (24) :1732-1739
[16]  
Jackson G, 2002, INT J CLIN PRACT, V56, P397
[17]  
Kothari Shyam S, 2002, Indian Heart J, V54, P404
[18]  
Laupland Kevin B, 2003, Can Respir J, V10, P48
[19]   Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension [J].
Leuchte, HH ;
Schwaiblmair, M ;
Baumgartner, RA ;
Neurohr, CF ;
Kolbe, T ;
Behr, F .
CHEST, 2004, 125 (02) :580-586
[20]   Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension - Comparison with inhaled nitric oxide [J].
Michelakis, E ;
Tymchak, W ;
Lien, D ;
Webster, L ;
Hashimoto, K ;
Archer, S .
CIRCULATION, 2002, 105 (20) :2398-2403